Skip to main content

Drug Interactions between Beqvez and repotrectinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

repotrectinib fidanacogene elaparvovec

Applies to: repotrectinib and Beqvez (fidanacogene elaparvovec)

Fidanacogene elaparvovec can cause liver problems, which may make the medication less effective in treating your condition. Using other medications that can also affect the liver such as repotrectinib after receiving fidanacogene elaparvovec may increase that risk. Symptoms of liver problems include fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. Blood tests to monitor liver function should be performed before and after treatment with fidanacogene elaparvovec. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Major

repotrectinib food

Applies to: repotrectinib

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib. This may increase the risk and/or severity of side effects such as dizziness, tiredness, muscle pain, nausea, change in your sense of taste, feeling numbness or tingling in your arms or legs, constipation, trouble with balance, shortness of breath, problems with thinking such as forgetfulness or confusion and hallucinations, as well as more serious side effects such severe or life-threatening inflammation of the lungs and liver injury. Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

fidanacogene elaparvovec food

Applies to: Beqvez (fidanacogene elaparvovec)

After receiving fidanacogene elaparvovec, alcohol consumption should be limited for at least 1 year. Fidanacogene elaparvovec can cause liver problems, which may make the medication less effective in treating your condition. Consuming other substances that can also affect the liver such as alcohol after receiving fidanacogene elaparvovec may increase that risk. Symptoms of liver problems include fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. Blood tests to monitor liver function should be performed before and after treatment with fidanacogene elaparvovec. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.